Sleep Disturbances in Alzheimer’s Disease Are Associated With Neuropsychiatric Symptoms and Antidementia TreatmentGarcía-Alberca, José María MD, PhD*†; Lara, José Pablo MD, PhD†; Cruz, Belén PhD*; Garrido, Victoria PhD*; Gris, Esther PhD*; Barbancho, Miguel Ángel MD, PhD†Journal of Nervous & Mental Disease: March 2013 - Volume 201 - Issue 3 - p 251–257 doi: 10.1097/NMD.0b013e3182848d04 Original Articles Abstract Author Information Abstract: Sleep disturbances (SDs) in Alzheimer’s disease (AD) may significantly affect the behavioral, functional, and cognitive capacities of patients to the point of becoming a major determinant of caregiver burden. We conducted a cross-sectional study in 125 patients with probable AD to assess the association of SDs with neuropsychiatric symptoms, cognitive and functional status of patients, and severity and duration of dementia and to ascertain the role of antidementia drugs in the treatment of SD. SDs were assessed using the questionnaire on sleep disorders in the Neuropsychiatric Inventory. The prevalence of SDs in this sample was 36%. SDs in patients with AD are significantly associated with depression (Wald’s test, 3.983; p < 0.05), disinhibition (Wald’s test, 5.522; p < 0.05), and aberrant motor behavior (Wald’s test, 7.430; p < 0.01). The patients treated with memantine presented lower mean SDs scores (t = 2.76; p < 0.001). These results highlight the need for a standardized and validated approach to the assessment of SDs in AD. *Memory and Alzheimer’s Disease Unit, Instituto Andaluz de Neurociencia y Conducta, Málaga, Spain; and †Cognitive Neurophysiology Unit, Centro de Investigaciones Médico-Sanitarias, University of Málaga, Málaga, Spain. Send reprint requests to José María García-Alberca, MD, PhD, Memory and Alzheimer’s Disease Unit, Instituto Andaluz de Neurociencia y Conducta, Alamos, 17. 29012 Málaga, Spain. E-mail: firstname.lastname@example.org. © 2013 Lippincott Williams & Wilkins, Inc.